Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462340 · ClinicalTrials.gov registry record · Phase 1
PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT05462340: Clinical Trial Phase 1 study, sponsored by Washington University School of Medicine.
NCT05462340 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 117 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462340, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to healthy controls.
Primary Outcome
The Primary Outcome Measure is volume of distribution (VT, represented as ml of plasma/cm\^3 of tissue) of alpha-7 nicotinic receptors (α7-nAChR) bound to by the \[18F\]ASEM radio tracer in the brain, comparing VT in people with SCZ with VT in otherwise healthy adults matched for all demographics (smoking status, age, sex, race/genotype, parental education).
Interventions
- DRUG [18F]ASEM
- DRUG [18F]AZAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2022-08-18 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 1 |
Why NCT05462340 stopped before completion
NCT05462340 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 2 interventions - of which [18F]ASEM is the first listed.
NCT05462340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05462340 about?
NCT05462340 is a clinical study titled "PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia". The purpose of this research is to use specialized brain imaging techniques, Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI), to learn more about the brain chemistry, e.g., how neurotransmitters and receptors in the brain function in people with schizophrenia compared to...
What is the current status of trial NCT05462340?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2022-08-18. Estimated completion is 2025-01-07.
What interventions are being tested in trial NCT05462340?
The interventions under investigation include: [18F]ASEM (DRUG), [18F]AZAN (DRUG).
Who is sponsoring clinical trial NCT05462340?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05462340's enrollment target sits among peer trials
117 499th of 2000 higher than 1,500 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI